Inflammopharmacology | 2021
Efficiency and safety: comparison between preoperative analgesia and postoperative analgesia using non-steroidal anti-inflammatory drugs in patients receiving arthroscopic knee surgery in a multicenter, randomized, controlled study.
Abstract
BACKGROUND\nThis study aimed to compare the efficiency regarding postoperative pain control, consumption of rescue drug, patients satisfaction and the safety of preoperative analgesia versus postoperative analgesia using non-steroidal anti-inflammatory drugs (NSAIDs) in patients who received arthroscopic knee surgery (AKS).\n\n\nMETHODS\nFour hundred and sixty-four patients who received AKS were recruited in this multicenter, randomized, controlled study. Subsequently, they were randomized into PRE group (N\u2009=\u2009232) and POST group (N\u2009=\u2009232). In PRE group, patients received celecoxib, meloxicam or rofecoxib from 2\xa0h pre-operation (Pre (-\u20092\xa0h)) to 48\xa0h post-operation for analgesia. In POST group, patients received celecoxib, meloxicam or rofecoxib from 4 to 48\xa0h post-operation for analgesia.\n\n\nRESULTS\nh and 12\xa0h; pain VAS at passive movement was reduced in PRE group than POST group at 6\xa0h, 12\xa0h and 24\xa0h. Additionally, consumption of rescue drug (pethidine) was decreased, while overall satisfaction was increased in PRE group compared to POST group. As for adverse events, the incidences of nausea, vomiting, constipation, drowsiness and dizziness were similar between PRE group and POST group. In subgroup analysis, the pain VAS score at passive movement at 6\xa0h and nausea and constipation incidences were distinctive among subgroups categorized by meloxicam, celecoxib and rofecoxib administration. However, no difference of other assessments was found among subgroups categorized by meloxicam, celecoxib and rofecoxib administration.\n\n\nCONCLUSION\nPreoperative analgesia using NSAIDs is more efficient and equivalently tolerable compared to postoperative analgesia using NSAIDs in patients who receive AKS.